TUMOR VS. MATCHED NORMAL cfRNA

WIPO Patent Application WO/2018/204377

A3

Compositions and methods for isolation and use of cfRNA are disclosed. Most preferably the cfRNA includes a patient-and tumor-specific mutation, and/or encodes a gene that is relevant in immune response or immune suppression. The identity and/or quantity of cfRNA can be further used for diagnosis of tumor, monitoring of prognosis of the tumor, monitoring the effectiveness of treatment provided to the patients, evaluating a treatment regime based on a likelihood of success of the treatment regime, and even as discovery tool that allows repeated and non-invasive sampling of a patient.

DANENBERG KATHLEEN (US)
RABIZADEH SHAHROOZ (US)
SOON-SHIONG PATRICK (US)

PCT/US2018/030472

March 28, 2019

May 01, 2018

Click for automatic bibliography generation  

NANTOMICS LLC (US)

C12Q1/6844; C12N15/10; C12Q1/6806; C12Q1/6869; C12Q1/6886; G16B5/00

WO2016077709A1

2016-05-19

US20170028044A1	2017-02-02
US20160026752A1	2016-01-28
US20140199681A1	2014-07-17
US20160030659A1	2016-02-04

GOLD, BERT ET AL.: "Do circulating tumor cells, exosomes, and circulating tumor nucleic acids have clinical utility? a report of the association for molecular pathology", THE JOURNAL OF MOLECULAR DIAGNOSTICS, vol. 17, no. 3, May 2015 (2015-05-01), pages 209 - 224, XP055584138
YI, XIN ET AL.: "The feasibility of using mutation detection in ctDNA to assess tumor dynamics", INTERNATIONAL JOURNAL OF CANCER, vol. 140, no. 12, 2 March 2017 (2017-03-02), pages 2642 - 2647, XP055584140
See also references of EP 3628057A4

FESSENMAIER, Martin et al. (US)

View/Download PDF      PDF Help

Previous Patent: VARIABLE OUTPUT FUEL PUMP HAVING A BLDC MOTOR AND CONTROL MODULE THEREFOR

Next Patent: ROTATABLE LIGHT